Researchers identify first drug to demonstrate therapeutic effect in a type of autism

May 20, 2010

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS). Behavioral symptoms of PMS fall under the autism spectrum disorder category. The research will be presented Friday at the International Meeting for Autism Research (IMFAR) in Philadelphia.

Previous research has shown that a in the brain called SHANK3 can cause absent or severely delayed language abilities, , and . Mount Sinai researchers developed mice with a mutant SHANK3 gene and observed a lapse in communication between in the brain, which can lead to learning problems. This communication breakdown indicated that the nerve cells were not maturing properly.

The researchers then injected the mice with a derivative of a compound called insulin-like growth factor-1 (IGF1), which is FDA-approved to treat growth failure in children. After two weeks of treatment, nerve cell communication was normal and adaptation of nerve cells to stimulation, a key part of learning and memory, was restored.

"The result of IGF1 treatment of these mice is an exciting development on the road to ultimate therapies for individuals with PMS," said Joseph Buxbaum, PhD, Director of the Seaver Autism Center for Research and Treatment at Mount Sinai School of Medicine. "If these data are further verified in additional preclinical studies, individuals with a SHANK3 mutation may benefit from treatments with compounds like this one."

Dr. Buxbaum and his team at the Seaver Autism Center will continue to evaluate the efficacy of IGF1 in mice. Patrick Hof, MD, Professor of Neuroscience at Mount Sinai School of Medicine, will specifically evaluate the effects of the compound on neuroanatomical changes. Additionally, Jacqueline Crawley, PhD, Senior Investigator at the National Institutes of Health, will study the effects on behavioral changes in the mice.

Explore further: Organovo has 3D-printed liver tissue for drug testing

Provided by The Mount Sinai Hospital

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Gene mutation is linked to autism-like symptoms in mice

Feb 23, 2010

(PhysOrg.com) -- When a gene implicated in human autism is disabled in mice, the rodents show learning problems and obsessive, repetitive behaviors, researchers at UT Southwestern Medical Center have found.

Study finds first-ever genetic animal model of autism

Dec 09, 2007

By introducing a gene mutation in mice, investigators have created what they believe to be the first accurate model of autism not associated with a broader neuropsychiatric syndrome, according to research presented at the ...

Multiple genes implicated in autism

Feb 09, 2009

(PhysOrg.com) -- By pinpointing two genes that cause autism-like symptoms in mice, researchers at MIT’s Picower Institute for Learning and Memory have shown for the first time that multiple, interacting genetic risk factors ...

Recommended for you

Organovo has 3D-printed liver tissue for drug testing

4 hours ago

(Medical Xpress)—The commercial release of 3D printed liver tissue was announced earlier this week. Organovo is the company behind the release. The product is intended for use for preclinical drug discovery ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.